EVOLUTION OF CONTRACEPTIVE IMPLANTS: A REVIEW
Oral contraceptives are widely used hormonal contraceptives compared to other dosage forms. There are modifications of hormonal contraceptives dosage forms to reduce side effects and improve effectivity and compliance during contraceptive usage. The implantable drug delivery system is a suitable contraception technique for women who are difficult to recall the time of use, such as pills. The contraceptive implant is a small size of rod, and it is placed in the upper arm subcutaneously. Many advantages by using contraceptive implants, such as high effectivity, easy to use, free from estrogen influences, fast recovery of the normal ovulatory cycle, safe for breastfeeding women, and safer for women that have the certain medical condition. However, implant removal procedures are becoming the problem because it requires trained personnel. The unscheduled period is also one of the disadvantages of implants. Although for most women, the implant could reduce blood loss when the period, for some cases it could prolong the period of time. In this article, we reviewed implant contraceptives development due to its application increased rapidly in the last decade. The history of implants, advantages, and disadvantages, and marketed products of the implant were also described in this article. The challenges and opportunities of the contraceptive implant development were summarized based on literature. Designing in situ forming implant and polymeric implant for contraception could be the great future in contraceptive implant development. Finally, contraceptive implants are promising hormonal contraception dosage forms to develop in unintended pregnancies prevention over the world.
2. Hubacher D, Mavranezouli I, McGinn E. Unintended pregnancy in sub-Saharan Africa: magnitude of the problem and potential role of contraceptive implants to alleviate it. Contraception 2008;78:73â€“8.
3. Hardee K, Harris S, Rodriguez M, Kumar J, Bakamjian L, Newman K, et al. Achieving the goal of the london summit on family planning by adhering to voluntary, Rights-based family planning: what can we learn from past experiences with coercion? Int Perspect Sex Reprod Health 2014; 40:206â€“14.
4. Hubacher D, Dorflinger L. Avoiding controversy in international provision of subdermal contraceptive implants. Contraception Elsevier Inc 2012;85:432â€“3.
5. Steiner MJ, Lopez LM, Grimes DA, Cheng L, Shelton J, Trussell J, et al. Sino-implant (II) a levonorgestrel-releasing two-rod implant: systematic review of the randomized controlled trials. Contraception 2010;81:197â€“201.
6. Mansour D. NexplanonÂ®: what ImplanonÂ® did next. BMJ Sex Reprod Heal. Br Med J Publishing Group 2010;36:187â€“9.
7. Santos A, Sinn Aw M, Bariana M, Kumeria T, Wang Y, Los. Drug-releasing implants: current progress, challenges and perspectives. J Mater Chem B; 2014. p. 1â€“28.
8. C Wright J, S Hoffman A. Long acting injections and implants. Long Act Inject Implant; 2012.
9. Kleiner LW, Wright JC, Wang Y. Evolution of implantable and insertable drug delivery systems. J Controlled Release 2014;181:1â€“10.
10. Folkman J, Long DM. The use of silicone rubber as a carrier for prolonged drug therapy. J Surg Res 1964;4:139â€“42.
11. Hoffman AS. The origins and evolution of controlledâ€ drug delivery systems. J Controlled Release 2008;132:153â€“63.
12. Vernon B, Wegner M. Controlled release. Encycl Biomater Biomed Eng. Taylor and Francis; 2004. p. 384â€“91.
13. Wright JC, Burgess DJ. Long acting injections and implants. Springer; 2011.
14. NHS Choices. Contraceptive implant; 2014. p. 1â€“2.
15. Wellings K, Jones KG, Mercer CH, Tanton C, Clifton S, Datta J, et al. The prevalence of unplanned pregnancy and associated factors in Britain: Findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Lancet 2013;382:1807â€“16.
16. Cameron ST, Glasier A, Chen ZE, Johnstone A, Dunlop C, Heller R. Effect of contraception provided at termination of pregnancy and incidence of subsequent termination of pregnancy. Int J Obstet Gynaecol 2012;119:1074â€“80.
17. Excellence C. Guideline-LARC guideline consultation table consultation; 2014. 2014. p. 1â€“25.
18. Nations U. World Family Planning; 2017. p. 1â€“43.
19. Moreau C, Bohet A, Hassoun D, Teboul M, Bajos N. Trends and determinants of use of long-acting reversible contraception use among young women in France: Results from three national surveys conducted between 2000 and 2010. Fertil Steril 2013;100:451â€“8.
20. Lader D. Opinions Survey Report No. 41 Contraception and Sexual Heath, 2008/09; 2009. p. 1â€“105.
21. Stoddard A, McNicholas C, Peipert JF. Efficacy and safety of long-acting reversible contraception. Drugs 2011;71:969â€“80.
22. Russo JA, Miller E, Gold MA. Myths and misconceptions about long-acting reversible contraception (LARC). J Adolesc Health 2013;52:S14-21.
23. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of ImplanonÂ® on menstrual bleeding patterns. Eur J Contracept Reprod Heal Care 2008;13:13â€“28.
24. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009;91:1646â€“53.
25. Funk S, Miller MM, Mishell DR, Archer DF, Poindexter A, Schmidt J, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005;71:319â€“26.
26. Rowlands S, Searle S. Contraceptive implants: current perspectives. Open Access J Contracept 2014;5:73â€“84.
27. Schnabel P, Merki-Feld GS, Malvy A, Duijkers I, Mommers E, Van Den Heuvel MW. Bioequivalence and X-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: A 3-year, randomized, double-blind study. Clin Drug Investig 2012;32:413â€“22.
28. Faculty of Sexual and Reproductive Healthcare. Introduction: Efectiveness of Contraceptive Method. UK Med Eligibility Criteria Contracept. UK: Faculty of Sexual and Reproductive Healthcare; 2016. p. 1â€“7.
29. Power J, French R, Cowan FM. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods for preventing pregnancy. Cochrane Libr. Wiley Online Library; 2007.
30. Glantz S, Glantz JC, Campbell-Heider N, Schaff E. NorplantÂ® use among urban minority women in the United States. Contraception 2000;61:83â€“90.
31. Brache V, Faundes A, Alvarez F, GarcÃa AG. Transition from Norplant to Jadelle in a clinic with extensive experience providing contraceptive implants. Contraception 2006;73:364â€“7.
32. Alam S, Baldwin JB, Tombros KA, Rinehart B, Shields WC, Swann AM. The single-rod contraceptive implant. Clin from Assoc Reprod Heal Prof; 2008. p. 7â€“9.
33. Fischer MA. Implanon: a new contraceptive implant. J Obstet Gynecol Neonatal Nurs 2008;37:361â€“8.
34. Darney PD, Monroe SE, Klaisle CM, Alvarado A. Clinical evaluation of the capronor contraceptive implant: preliminary report. Am J Obstet Gynecol 1989;160:1292â€“5.
35. Jacobstein R, Polis CB. Progestin-only contraception: Injectables and implants. Best Pract Res Clin Obstet Gynaecol 2014;28:795â€“806.
36. Reproductive Health Supplies Coalition. Caucus on New and Underused Reproductive Health Technologies. Cochrane Database Syst Rev; 2011. p. 12â€“4.
37. Faculty of Sexual and Reproductive Healthcare. Clinical Guidance: Drug Interactions with Hormonal Contraception Drug Interactions with Hormonal Contraception; 2017. p. 1â€“12.
38. Mansour HM, Sohn MJ, Al-Ghananeem A, DeLuca PP. Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. Int J Mol Sci 2010;11:3298â€“322.
39. Solorio L, Carlson A, Zhou H, Exner AA. Implantable drug delivery systems. In: Bader RA, Putnam DA. editors. Eng Polym Syst Improv Drug Deliv. First Edit. John Wiley and Sons, Inc; 2014. p. 191â€“225.
40. Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Delivery 2010;7:429â€“44.
41. Gad HA, El-Nabarawi MA, El-Hady SSA. Formulation and evaluation of PLA and PLGA in situ implants containing secnidazole and/or doxycycline for treatment of periodontitis. Aaps Pharmscitech 2008;9:878.
42. LÃ¼ JM, Wang X, Marin Muller C, Wang H, Lin PH, Yao Q, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 2009;9:325â€“41.
43. Shuwisitkul D. Biodegradable implants with different drug release profiles. Freie Universitat Berlin; 2011.
44. Patel B, Chakraborty S. Biodegradable polymers: emerging excipients for the pharmaceutical and medical device industries. J Excipients Food Chem 2013;4:126-57.
45. Dorati R, Conti B, Colzani B, Dondi D, Lazzaroni S, Modena T, et al. Ivermectin controlled release implants based on poly-D,L-lactide and poly-Îµ-caprolactone. J Drug Delivery Sci Technol 2018;46:101â€“10.
46. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm 2008;364:298â€“327.
47. Teo AJT, Mishra A, Park I, Kim YJ, Park WT, Yoon YJ. Polymeric biomaterials for medical implants and devices. ACS Biomater Sci Eng 2016;2:454â€“72.
48. Zhou J, Huang X, Zheng D, Li H, Herrler T, Li Q. Oriental nose elongation using an L-shaped polyethylene sheet implant for combined septal spreading and extension. Aesthetic Plast Surg 2014;38:295â€“302.
49. Rahimi A, Mashak A. Review on rubbers in medicine: natural, silicone and polyurethane rubbers. Plast Rubber Compos 2013;42:223â€“30.
50. Roohpour N, Wasikiewicz JM, Moshaverinia A, Paul D, Grahn MF, Rehman IU, et al. Polyurethane membranes modified with isopropyl myristate as a potential candidate for encapsulating electronic implants: a study of biocompatibility and water permeability. Polymers (Basel) 2010;2:102â€“19.
51. Kirsten S, Uhlemann J, Braunschweig M, Wolter KJ. Packaging of electronic devices for long-term implantation. Electron Technol (ISSE), 2012 35th Int Spring Semin. IEEE; 2012. p. 123â€“7.
52. Patlolla A, Collins G, Livingston Arinzeh T. Solvent-dependent properties of electrospun fibrous composites for bone tissue regeneration. Acta Biomater 2010;6:90â€“101.
53. Ulery BD, Nair LS, Laurencin TC. Biomedical applications of biodegradable polymers. J Environ Polym Degrad 1993;49:65â€“80.
54. Ramchandran D, Upadhyay UD. Implants: the next generation. Popul Reports Ser K Inject Implant; 2007. p. 1â€“19.
55. Hohmann H, Creinin MD. The contraceptive implant. Clin Obstet Gynecol 2007;50:907â€“17.
56. Liu Q, Zhang H, Zhou G, Xie S, Zou H, Yu Y, et al. In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants. Int J Pharm 2010;397:122â€“9.
57. Li H, Liu T, Zhu Y, Fu Q, Wu W, Deng J, et al. An in situ-forming phospholipid-based phase transition gel prolongs the duration of local anesthesia for ropivacaine with minimal toxicity. Acta Biomater 2017;58:136â€“45.
58. Avachat AM, Kapure SS. Asenapine maleate in situ forming biodegradable implant: an approach to enhance bioavailability. Int J Pharm 2014;477:64â€“72.
59. Solanki HK, Thakkar JH, Jani GK. Recent advances in implantable drug delivery tm. Int J Pharm Sci Rev Res 2010;4:168â€“77.
60. Tsai NC, Sue CY. Review of MEMS-based drug delivery and dosing systems. Sensors Actuators A Phys 2007;134:555â€“64.
61. Kotzar G, Freas M, Abel P, Fleischman A, Roy S, Zorman C, et al. Evaluation of MEMS materials of construction for implantable medical devices. Biomaterials 2002;23:2737â€“50.
62. Dash AK, Cudworth GC. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 1998;40:1â€“12.
63. Abel PU, Von Woedtke T. Biosensors for in vivo glucose measurement: can we cross the experimental stage. Biosens Bioelectron 2002;17:1059â€“70.